Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
Allogene Therapeutics (Nasdaq: ALLO) announced its participation in two investor conferences in January and February 2023. The company will attend the B. Riley Securities’ 3rd Annual Oncology Conference on January 18, 2023, at 7:00 AM PT and the 5th Annual Guggenheim Oncology Days on February 9, 2023, at 6:35 AM PT. Webcasts from these events will be available on the company's website, allowing for replay for 30 days. Allogene is developing allogeneic CAR T cell therapies, aiming to provide more accessible cancer treatments. For updates, visit www.allogene.com.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will participate in two upcoming investor conferences.
B. Riley Securities’ 3rd Annual Oncology Conference
Wednesday, January 18, 2023
7:00AM PT/10:00AM ET
5th Annual Guggenheim Oncology Days
Thursday, February 9, 2023
6:35AM PT/9:35AM ET
Any available webcasts will be posted to the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on the Company's website for approximately 30 days.
About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow @AllogeneTx on Twitter and LinkedIn.
Cautionary Note on Forward-Looking Statements for Allogene
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability to develop allogeneic CAR T products for cancer and the potential benefits of AlloCAR T. Various factors may cause differences between Allogene’s expectations and actual results as discussed in greater detail in Allogene’s filings with the Securities and Exchange Commission (SEC), including without limitation in its Form 8-K filed on November 29, 2022 and under the “Risk Factors” heading of its Form 10-Q for the quarter ended September 30, 2022. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.
Allogene Media/Investor Contact:
Christine Cassiano
Chief Communications Officer
(714) 552-0326
Christine.Cassiano@allogene.com
Jessica Bernstein
Senior Manager, Corporate and Internal Communications
Jessica.Bernstein@allogene.com
FAQ
What conferences is Allogene Therapeutics participating in January 2023?
What is the stock symbol for Allogene Therapeutics?
Where can I find the webcasts for Allogene's investor conferences?
What is the focus of Allogene Therapeutics?
When will the replay of the webcasts be available for Allogene's conferences?
